Header Logo

Connection

Nicola Klein to Adolescent

This is a "connection" page, showing publications Nicola Klein has written about Adolescent.
Connection Strength

3.481
  1. Informing Maternal Immunization Trials: An Observational Study to Assess Background Rates of Maternal, Pregnancy, and Neonatal/Infant Outcomes. Pediatr Infect Dis J. 2025 Feb 01; 44(2S):S130-S134.
    View in: PubMed
    Score: 0.134
  2. Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children. Influenza Other Respir Viruses. 2024 Oct; 18(10):e70022.
    View in: PubMed
    Score: 0.130
  3. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 01; 154(2).
    View in: PubMed
    Score: 0.129
  4. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.129
  5. Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age. N Engl J Med. 2023 Dec 14; 389(24):2245-2255.
    View in: PubMed
    Score: 0.123
  6. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.118
  7. COVID-19 vaccination protects children and adolescents. Lancet Infect Dis. 2023 01; 23(1):5-6.
    View in: PubMed
    Score: 0.113
  8. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.109
  9. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
    View in: PubMed
    Score: 0.095
  10. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine. 2018 04 19; 36(17):2356-2363.
    View in: PubMed
    Score: 0.083
  11. Use of acellular pertussis vaccines in the United States: can we do better? Expert Rev Vaccines. 2017 12; 16(12):1175-1179.
    View in: PubMed
    Score: 0.081
  12. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine. 2017 05 09; 35(20):2668-2675.
    View in: PubMed
    Score: 0.078
  13. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.074
  14. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
    View in: PubMed
    Score: 0.074
  15. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016 Mar; 137(3):e20153326.
    View in: PubMed
    Score: 0.072
  16. Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Sep; 32(9):990-7.
    View in: PubMed
    Score: 0.061
  17. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ. 2013 Jul 17; 347:f4249.
    View in: PubMed
    Score: 0.060
  18. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013 Jul; 40(7):534-8.
    View in: PubMed
    Score: 0.060
  19. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013 Jun; 131(6):e1716-22.
    View in: PubMed
    Score: 0.059
  20. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013 Jul; 57(2):197-204.
    View in: PubMed
    Score: 0.059
  21. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012 Dec; 166(12):1140-8.
    View in: PubMed
    Score: 0.057
  22. Epidemiologic and clinical features of Bell's palsy among children in Northern California. Neuroepidemiology. 2012; 38(4):252-8.
    View in: PubMed
    Score: 0.056
  23. An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine. 2012 Jun 29; 30(31):4585-7.
    View in: PubMed
    Score: 0.055
  24. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011 May; 127(5):e1139-46.
    View in: PubMed
    Score: 0.051
  25. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010 Jul; 29(7):613-7.
    View in: PubMed
    Score: 0.049
  26. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010 Jan 22; 28(4):1062-8.
    View in: PubMed
    Score: 0.046
  27. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
    View in: PubMed
    Score: 0.034
  28. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):83-90.
    View in: PubMed
    Score: 0.034
  29. Trends in Gonorrhea and Chlamydia Testing and Infections Across the COVID-19 Pandemic in Adolescents and Young Adults in an Integrated Health System. J Adolesc Health. 2024 Dec; 75(6):952-957.
    View in: PubMed
    Score: 0.032
  30. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. JMIR Public Health Surveill. 2024 Jun 25; 10:e53807.
    View in: PubMed
    Score: 0.032
  31. Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstet Gynecol. 2024 Aug 01; 144(2):215-222.
    View in: PubMed
    Score: 0.032
  32. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged =18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 28; 73(12):271-276.
    View in: PubMed
    Score: 0.031
  33. Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):168-174.
    View in: PubMed
    Score: 0.031
  34. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged =18 Years - VISION and IVY Networks, September 2023-January 2024. MMWR Morb Mortal Wkly Rep. 2024 Feb 29; 73(8):180-188.
    View in: PubMed
    Score: 0.031
  35. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023 May 26; 72(21):579-588.
    View in: PubMed
    Score: 0.030
  36. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.029
  37. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.029
  38. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
    View in: PubMed
    Score: 0.029
  39. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.027
  40. A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine. 2022 02 23; 40(9):1246-1252.
    View in: PubMed
    Score: 0.027
  41. Evaluation of Trends in Homeschooling Rates After Elimination of Nonmedical Exemptions to Childhood Immunizations in California, 2012-2020. JAMA Netw Open. 2022 02 01; 5(2):e2146467.
    View in: PubMed
    Score: 0.027
  42. The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes. Pediatrics. 2021 12 01; 148(6).
    View in: PubMed
    Score: 0.027
  43. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.027
  44. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.027
  45. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29; 70(43):1520-1524.
    View in: PubMed
    Score: 0.027
  46. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August 2021. MMWR Morb Mortal Wkly Rep. 2021 09 17; 70(37):1291-1293.
    View in: PubMed
    Score: 0.026
  47. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.026
  48. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
    View in: PubMed
    Score: 0.026
  49. Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. Vaccine. 2021 06 16; 39(27):3614-3620.
    View in: PubMed
    Score: 0.026
  50. Temporal Trends in Undervaccination: A Population-Based Cohort Study. Am J Prev Med. 2021 07; 61(1):64-72.
    View in: PubMed
    Score: 0.026
  51. Evaluating the Association of Stillbirths After Maternal Vaccination in the Vaccine Safety Datalink. Obstet Gynecol. 2020 12; 136(6):1086-1094.
    View in: PubMed
    Score: 0.025
  52. SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics - Eight U.S. Health Care Centers, March 1-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 23; 69(38):1355-1359.
    View in: PubMed
    Score: 0.025
  53. Epidemiology and Clinical Outcomes of Hospitalizations for Acute Respiratory or Febrile Illness and Laboratory-Confirmed Influenza Among Pregnant Women During Six Influenza Seasons, 2010-2016. J Infect Dis. 2020 04 27; 221(10):1703-1712.
    View in: PubMed
    Score: 0.024
  54. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.023
  55. Uptake and safety of hepatitis A vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2019 10 16; 37(44):6648-6655.
    View in: PubMed
    Score: 0.023
  56. Inactivated influenza vaccine and spontaneous abortion in the Vaccine Safety Datalink in 2012-13, 2013-14, and 2014-15. Vaccine. 2019 10 16; 37(44):6673-6681.
    View in: PubMed
    Score: 0.023
  57. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.023
  58. Uptake and safety of Hepatitis B vaccination during pregnancy: A Vaccine Safety Datalink study. Vaccine. 2018 10 01; 36(41):6111-6116.
    View in: PubMed
    Score: 0.021
  59. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.020
  60. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017 12 14; 35(49 Pt B):6879-6884.
    View in: PubMed
    Score: 0.020
  61. Maternal and Infant Outcomes After Human Papillomavirus Vaccination in the Periconceptional Period or During Pregnancy. Obstet Gynecol. 2017 09; 130(3):599-608.
    View in: PubMed
    Score: 0.020
  62. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
    View in: PubMed
    Score: 0.020
  63. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
    View in: PubMed
    Score: 0.020
  64. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
    View in: PubMed
    Score: 0.019
  65. Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. Vaccine. 2016 Feb 10; 34(7):968-73.
    View in: PubMed
    Score: 0.018
  66. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
    View in: PubMed
    Score: 0.018
  67. Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy. Obstet Gynecol. 2015 Nov; 126(5):1069-74.
    View in: PubMed
    Score: 0.018
  68. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. JAMA. 2015 Oct 20; 314(15):1581-7.
    View in: PubMed
    Score: 0.018
  69. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 Mar; 137(3):868-78.
    View in: PubMed
    Score: 0.017
  70. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015 Sep; 34(9):983-91.
    View in: PubMed
    Score: 0.017
  71. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA. 2014 Nov 12; 312(18):1897-904.
    View in: PubMed
    Score: 0.016
  72. Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink sites. Prev Med. 2014 Oct; 67:316-9.
    View in: PubMed
    Score: 0.016
  73. Live vaccine use and safety in DiGeorge syndrome. Pediatrics. 2014 Apr; 133(4):e946-54.
    View in: PubMed
    Score: 0.016
  74. Vaccinations given during pregnancy, 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb; 46(2):150-7.
    View in: PubMed
    Score: 0.016
  75. Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. Cancer Epidemiol Biomarkers Prev. 2013 Jun; 22(6):1129-32.
    View in: PubMed
    Score: 0.015
  76. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pediatr Infect Dis J. 2013 Feb; 32(2):163-8.
    View in: PubMed
    Score: 0.015
  77. Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact. Cancer Causes Control. 2013 Feb; 24(2):403-7.
    View in: PubMed
    Score: 0.014
  78. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Nov 26; 30(50):7253-9.
    View in: PubMed
    Score: 0.014
  79. Immunization and Bell's palsy in children: a case-centered analysis. Am J Epidemiol. 2012 May 01; 175(9):878-85.
    View in: PubMed
    Score: 0.014
  80. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012 Feb; 271(2):193-203.
    View in: PubMed
    Score: 0.013
  81. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011 Oct 26; 29(46):8279-84.
    View in: PubMed
    Score: 0.013
  82. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine. 2011 Oct 26; 29(46):8302-8.
    View in: PubMed
    Score: 0.013
  83. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. Vaccine. 2011 Sep 02; 29(38):6592-7.
    View in: PubMed
    Score: 0.013
  84. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.013
  85. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
    View in: PubMed
    Score: 0.012
  86. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009 Feb; 123(2):e228-34.
    View in: PubMed
    Score: 0.011

© 2025 Kaiser Permanente